Ralph A. DeFronzo, M.D.
Dr. Ralph DeFronzo's major interests focus on the
pathogenesis and treatment of type 2 diabetes mellitus and the central role of
insulin resistance in the metabolic-cardiovascular cluster of disorders known
collectively as the Insulin Resistance Syndrome. Using the euglycemic insulin clamp technique
in combination with radioisotope turnover methodology, limb catheterization,
indirect calorimetry, and muscle biopsy, he has helped to define the
biochemical and molecular disturbances responsible for insulin resistance in
type 2 diabetes mellitus.
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy
D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb 3;124(2):509-14.
Doiron B, Hu W, Norton L, DeFronzo RA. Lentivirus
shRNA Grb10 targeting the pancreas induces apoptosis and improved
glucose tolerance due to decreased plasma glucagon levels. Diabetologia. 2012 Mar;55(3):719-28.
DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010 Jul;53(7):1270-87.
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95.
Professor & Division Chief
M.D., Medicine, Harvard Medical School, 1969
M.S., Medicine, Boston College Graduate School of Biology, 1969
BMS, Medicine, Dartmouth Medical School
B.S., Biology/Biochemistry, Yale University, 1964
Phone: (210) 567-6691
Stephen (Xi) Chen
Feng Dong (M.S.)
Marjorie Molina-Carrion (M.S.)